Skip to content
10-Q

Quarterly Report

Lazuriton Nano Biotechnology (U.S.A.) Inc.

0001640334-23-001211

← back to feed
Filed
Jul 5, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2022 · Jul 5, 2023 100M sh
Operating Cash Flow Q1 2022 · Mar 31, 2022 $0
Operating Cash Flow Q1 2022 · Mar 31, 2021 $0
Stockholders Equity Q1 2022 · Mar 31, 2022 −$379.53K
Stockholders Equity Q1 2022 · Dec 31, 2021 −$368.58K
Stockholders Equity Q1 2022 · Mar 31, 2021 −$330.73K
Stockholders Equity Q1 2022 · Dec 31, 2020 −$319.78K
Current Liabilities Q1 2022 · Mar 31, 2022 $380.88K
Current Liabilities Q1 2022 · Dec 31, 2021 $369.93K
Total Liabilities Q1 2022 · Mar 31, 2022 $380.88K
Total Liabilities Q1 2022 · Dec 31, 2021 $369.93K
Current Assets Q1 2022 · Mar 31, 2022 $1.35K
Current Assets Q1 2022 · Dec 31, 2021 $1.35K
Total Assets Q1 2022 · Mar 31, 2022 $1.35K
Total Assets Q1 2022 · Dec 31, 2021 $1.35K
Sga Expense Q1 2022 · Mar 31, 2022 $10.95K
Sga Expense Q1 2022 · Mar 31, 2021 $10.95K
Net Income Q1 2022 · Mar 31, 2022 −$10.95K
Net Income Q1 2022 · Mar 31, 2021 −$10.95K
Operating Income Q1 2022 · Mar 31, 2022 −$10.95K
Operating Income Q1 2022 · Mar 31, 2021 −$10.95K
Revenue Q1 2022 · Mar 31, 2022 $0
Revenue Q1 2022 · Mar 31, 2021 $0